Albireo Reports 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Albireo Pharma (ALBO) Reports FY16 Loss of $13.16
March 14, 2017 7:33 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported FY16 EPS of ($13.16), versus ($25.49) reported last year. Revenue for the year came in at $11.4 million, versus $5.1 million reported last year.
For earnings history and earnings-related data on Albireo Pharma (ALBO) click here.
... More